Kidney Week 2025
Summaries from Kidney Week 2025, held from November 5 – 9, 2025.
Tirzepatide improves kidney-related outcomes compared to dulaglutide in high-risk patients with type 2 diabetes, analysis suggests
Presenter: Sophia Zoungas, PhD, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Tirzepatide vs. dulaglutide is associated with reduced major kidney events in patients with type 2 diabetes, CVD, and very high-risk kidney diseases. Abstract FR-OR087. Presented November 7, 2025.
SGLT2 inhibitors slow chronic kidney disease across a broad range of kidney function, analysis shows
Presenter: Brendon L. Neuen, MBBS, MSc, PhD, The George Institute for Global Health, Sydney, New South Wales, Australia
Impact of glomerular filtration rate and albuminuria on the effects of SGLT2 inhibitors on kidney outcomes. Abstract FR-OR092. Presented November 7, 2025.
Dual BAFF/APRIL inhibitor povetacicept shows early promise in phase 1/2 study of IgA nephropathy and primary membranous nephropathy
Presenter: James A. Tumlin, MD, Emory University School of Medicine, Atlanta, GA
Efficacy and safety of povetacicept in patients with IgAN and primary membranous nephropathy (pMN) at 48 Weeks of treatment: the RUBY-3 study. Abstract SA-OR091. Presented November 8, 2025.
Omega-3 fatty acid supplementation reduces cardiovascular events in patients on hemodialysis in a randomized controlled trial
Presenter: Charmaine E. Lok, MD, University of Toronto, Ontario, Canada
Protection Against Incidences of Serious Cardiovascular Events Study with daily fish oil supplementation in patients on dialysis (PISCES). Abstract FR-OR082. Presented November 9, 2025.
Kidney benefits persist long-term after treatment with oral methylprednisolone in patients with IgA nephropathy, study shows
Presenter: Muh Geot Wong, MBBS, PhD, Concord Repatriation General Hospital, Concord, New South Wales, Australia
Long-term effect of oral methylprednisolone on kidney outcomes in patients with IgAN: TESTING-ON, a post-trial observational study. Abstract SA-OR092. Presented November 8, 2025.
Conservative strategy speeds recovery in patients with acute kidney injury requiring dialysis, study shows
Presenter: Chi-yuan Hsu, MD, University of California San Francisco
Liberation from Acute Dialysis (LIBERATE-D). Abstract FR-OR083. Presented November 7, 2025.
Rilparencel autologous cell therapy preserved kidney function in phase 2 trial, data show
Presenter: Bruce F. Culleton, MD, nephrologist and Chief Executive Officer, ProKidney, Winston-Salem, NC
Renal autologous cell therapy in diabetes and CKD. Abstract TH-PO1203. Presented November 6, 2025.
Atacicept significantly reduced proteinuria in patients with IgA nephropathy, phase 3 data show
Presenter: Richard A. Lafayette, MD, Stanford University Medical Center, Stanford, CA
ORIGIN 3: A phase 3 trial of atacicept in IgAN. Abstract TH-OR083. Presented November 6, 2025.
Finerenone has favorable benefit/risk profile in people with type 1 diabetes and chronic kidney disease, phase 3 results suggest
Presenter: Hiddo Lambers Heerspink, PhD, PharmD, University Medical Center Groningen, Netherlands
Finerenone in CKD and type 1 diabetes. Abstract TH-OR082. Presented November 6, 2025.